Aspen’s earnings growth squeezed by global tax rules
OECD’s BEPS Pillar 2 tax has driven the company’s effective tax rate up to 25%
03 March 2025 - 18:06
Aspen Pharmacare’s latest results reveal strong revenue growth, particularly in commercial pharmaceuticals and manufacturing, but were squeezed by the unexpected effect of the Organisation for Economic Co-operation and Development’s (OECD’s) Base Erosion and Profit Shifting (BEPS) Pillar 2 tax framework.
The application of the tax has driven Aspen’s effective tax rate up to 25%, diluting profit growth despite strong revenue performance...
Would you like to comment on this article?
Sign up (it's quick and free) or sign in now.
Please read our Comment Policy before commenting.
Subscribe now to unlock this article.
Support BusinessLIVE’s award-winning journalism for R129 per month (digital access only).
There’s never been a more important time to support independent journalism in SA. Our subscription packages now offer an ad-free experience for readers.
Cancel anytime.
Questions? Email helpdesk@businesslive.co.za or call 0860 52 52 00. Got a subscription voucher? Redeem it now.